An advisory panel to the Centers for Disease Control and Prevention (CDC) on Thursday voted 15 – 0 to “preferentially recommend” mRNA COVID vaccines Pfizer and Moderna over the Johnson & Johnson (J&J) shot for adults 18 years and older.
The recommendation came after the agency’s advisory panel said the rate of rare blood-clotting disorders following the J&J vaccine was higher than expected. The CDC signed off on the panel’s updated guidance late Thursday.
The Advisory Committee on Immunization and Practices (ACIP) effectively discouraged vaccine providers and adults from using the J&J’s shot — marking the first time the panel expressed a preference for a specific type of COVID vaccine.
The panel stopped short of recommending the vaccine be pulled from the market. J&J’s vaccine will remain an option for people who are “unable or unwilling” to receive mRNA vaccines, The New York Times reported.
The ACIP said the interim recommendation applies to J&J’s primary series vaccine doses and its booster dose.
Panel members requested stronger language be used in the guidance, but CDC officials said the strength of the recommendations would be made clear in the clinical considerations.
read more:
https://childrenshealthdefense.org/defender/cdc-johnson-pfizer-moderna-blood-clot-risk/
Replies